[go: up one dir, main page]

MA31384B1 - Nouvelles molécules d'anticorps et d'acides nucléiques se fixant à la protéine hsp90 de stress fongique - Google Patents

Nouvelles molécules d'anticorps et d'acides nucléiques se fixant à la protéine hsp90 de stress fongique

Info

Publication number
MA31384B1
MA31384B1 MA32355A MA32355A MA31384B1 MA 31384 B1 MA31384 B1 MA 31384B1 MA 32355 A MA32355 A MA 32355A MA 32355 A MA32355 A MA 32355A MA 31384 B1 MA31384 B1 MA 31384B1
Authority
MA
Morocco
Prior art keywords
nucleic acid
acid molecules
stress protein
novel antibody
protein hsp90
Prior art date
Application number
MA32355A
Other languages
Arabic (ar)
English (en)
Inventor
James Burnie
Philipp Wechner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31384B1 publication Critical patent/MA31384B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention porte sur un peptide scfv comprenant un domaine vh et un domaine vl liés par un espaceur d'acide aminé. Le domaine vh comprend une séquence présentant au moins 80 % d'identité avec la séquence seq id no 64. Le domaine vl comprend une séquence présentant au moins 80 % d'identité avec la séquence seq id no 66. Le peptide scfv comprend également la substitution ou la délation d'un acide aminé du domaine vh à la position correspondant à c28.
MA32355A 2007-04-27 2009-11-20 Nouvelles molécules d'anticorps et d'acides nucléiques se fixant à la protéine hsp90 de stress fongique MA31384B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07107140 2007-04-27
EP07113353 2007-07-27
PCT/EP2008/055006 WO2008132134A1 (fr) 2007-04-27 2008-04-24 Nouvelles molécules d'anticorps et d'acides nucléiques se fixant à la protéine hsp90 de stress fongique

Publications (1)

Publication Number Publication Date
MA31384B1 true MA31384B1 (fr) 2010-05-03

Family

ID=39717534

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32355A MA31384B1 (fr) 2007-04-27 2009-11-20 Nouvelles molécules d'anticorps et d'acides nucléiques se fixant à la protéine hsp90 de stress fongique

Country Status (21)

Country Link
US (3) US20100113355A1 (fr)
EP (2) EP2144932A1 (fr)
JP (1) JP2010524485A (fr)
KR (1) KR20100017387A (fr)
CN (1) CN101679517A (fr)
AR (1) AR066311A1 (fr)
AU (1) AU2008244308A1 (fr)
BR (1) BRPI0810827A2 (fr)
CA (1) CA2685136A1 (fr)
CL (1) CL2008001202A1 (fr)
CR (1) CR11059A (fr)
EA (1) EA200901441A1 (fr)
EC (1) ECSP099765A (fr)
GT (1) GT200900276A (fr)
IL (1) IL201445A0 (fr)
MA (1) MA31384B1 (fr)
MX (1) MX2009011595A (fr)
PE (1) PE20090728A1 (fr)
TN (1) TN2009000442A1 (fr)
TW (1) TW200902714A (fr)
WO (2) WO2008132134A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2016014839A2 (fr) * 2014-07-23 2016-01-28 Ohio State Innovation Foundation Méthodes et compositions associées à des fragments d'anticorps qui se lient à la glycoprotéine 72 associée aux tumeurs (tag 72)
CN105652011B (zh) * 2014-11-20 2017-09-22 深圳市安群生物工程有限公司 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法
CN113845591B (zh) * 2018-10-30 2023-10-31 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
US20240398982A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732852A (en) * 1981-11-20 1988-03-22 Cetus Corporation Site directed peptidase cleavage
US4670382A (en) 1983-12-02 1987-06-02 Temple University--of the Commonwealth System of Higher Education Monoclonal antibody to Candida albicans cytoplasmic antigens and methods of preparing same
US4806465A (en) * 1984-01-16 1989-02-21 Temple University Of The Commonwealth System Of Higher Education Cytoplasmic antigens of candida albicans and methods of using the same
GB8506373D0 (en) 1985-03-12 1985-04-11 Axon Healthcare Ltd Antigens antibodies
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
ES2287044T3 (es) 2000-01-25 2007-12-16 Oklahoma Medical Research Foundation Procedimiento universal para el replegamiento de proteinas recombinantes.
GB0008305D0 (en) * 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
AU2001272001A1 (en) 2000-07-14 2002-01-30 Healthcite, Inc. Method and system for providing medical information
EP1423080A4 (fr) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp Procede de traitement de troubles proliferatifs d'origine genetique par des inhibiteurs de hsp90
GB0127983D0 (en) 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0409077D0 (en) * 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
US20080038267A1 (en) * 2004-07-02 2008-02-14 Neutec Pharma Limited Treatment Of Cancer
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (fr) 2007-04-27 2008-11-06 Novartis Ag Composition d'immunoglobulines

Also Published As

Publication number Publication date
JP2010524485A (ja) 2010-07-22
KR20100017387A (ko) 2010-02-16
CA2685136A1 (fr) 2008-11-06
ECSP099765A (es) 2009-12-28
EP2144932A1 (fr) 2010-01-20
US20090136484A1 (en) 2009-05-28
MX2009011595A (es) 2009-12-08
CN101679517A (zh) 2010-03-24
TN2009000442A1 (en) 2011-03-31
IL201445A0 (en) 2010-06-16
US20100113355A1 (en) 2010-05-06
EA200901441A1 (ru) 2010-04-30
US7722869B2 (en) 2010-05-25
GT200900276A (es) 2010-05-21
CL2008001202A1 (es) 2008-12-19
WO2008132134A9 (fr) 2009-07-09
PE20090728A1 (es) 2009-07-02
TW200902714A (en) 2009-01-16
US20100166758A1 (en) 2010-07-01
WO2008132152A1 (fr) 2008-11-06
AU2008244308A1 (en) 2008-11-06
AR066311A1 (es) 2009-08-12
BRPI0810827A2 (pt) 2014-10-29
EP2152746A1 (fr) 2010-02-17
WO2008132134A1 (fr) 2008-11-06
CR11059A (es) 2009-11-20

Similar Documents

Publication Publication Date Title
MA31384B1 (fr) Nouvelles molécules d'anticorps et d'acides nucléiques se fixant à la protéine hsp90 de stress fongique
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
WO2004019878A3 (fr) Adzymes et leurs utilisations
MA31138B1 (fr) Anticorps humains de haute affinite diriges contre le recepteur humain de l'il-4
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MX2020002995A (es) Metodo de conjugacion de transglutaminasa y ligador.
MA31940B1 (fr) Produits de construction de liaison a un antigene
MA35175B1 (fr) Domaines de liaison du serum deimmunise et leur utilisation pour prolonger le demi-vie du serum
MA35035B1 (fr) Anticorps polypeptidiques qui antagonisent les cd40
EA201100527A1 (ru) Биологические продукты
MA31092B1 (fr) Anticorps humains contre le delta-like ligand 4 humain.
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
WO2021041715A3 (fr) Compositions comprenant des mutations de fc d'igg et leurs utilisations
MA29226B1 (fr) Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
RS53168B (en) Antibodies and Immunoconjugates and Their Use
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
EA201200526A1 (ru) Поливалентные антитела, стабилизированные дисульфидом
MA30689B1 (fr) Derives de leptomycine
CA2783820C (fr) Variants de proteases
MX2010004660A (es) NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.
JP2016531546A5 (fr)
EA200870208A1 (ru) Конструкт однодоменного антитела